In recent work, it has been demonstrated that the CD26 expression in several NSCLC cell lines is associated with their invasive capacity and that treatment with a CD26 inhibitor, such as the flavonoid apigenin, suppresses CD26 expression and consequently inhibits tumor progression [16]. This evidence concerns the gene DPP4 and non-small cell lung carcinoma.